Zebra Biologics is Drug Discovery in United States that focus on novel antibody business. Founded in 2013. They cover business area such as developer, novel antibody and biological drug, clinical need, multiple disease area, cellular function-base screening, selection, fully human therapeutic biologic, peptide, protein, DNA-encode combinatorial library, human antibody, medical company, diabetes, obesity, cancer, neurological disease.
2013
( 11 years old in 2024 )
Novel Antibody
-
1041 Old Marlboro Road
Concord, MA 01742
United States
Private
developernovel antibody and biological drugclinical needmultiple disease areacellular function-base screeningselectionfully human therapeutic biologicpeptideproteinDNA-encode combinatorial libraryhuman antibodymedical companydiabetesobesitycancerneurological disease
* We use standard office opening hours in near Zebra Biologics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Zebra Biologics is Drug Discovery business from United States that founded in 2013 (11 years old in 2024), Zebra Biologics business is focusing on Novel Antibody.
Zebra Biologics headquarter office and corporate office address is located in 1041 Old Marlboro Road Concord, MA 01742 United States.
Zebra Biologics was founded in United States.
In 2024, Zebra Biologics is currently focus on novel antibody sector.
Above is snippet of Google Trends for "novel antibody" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Zebra Biologics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
